메뉴 건너뛰기




Volumn 312, Issue 5, 2017, Pages G407-G412

Rationale for the use of statins in liver disease

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

EID: 85018728261     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00441.2016     Document Type: Review
Times cited : (54)

References (55)
  • 1
    • 65349094504 scopus 로고    scopus 로고
    • Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial
    • Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García- Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136: 1651–1658, 2009. doi:10.1053/j.gastro.2009.01.043.
    • (2009) Gastroenterology , vol.136 , pp. 1651-1658
    • Abraldes, J.G.1    Albillos, A.2    Bañares, R.3    Turnes, J.4    González, R.5    García- Pagán, J.C.6    Bosch, J.7
  • 7
    • 85005808117 scopus 로고    scopus 로고
    • Hepatotoxicity of statins and other lipid-lowering agents
    • Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 37: 173–178, 2017. doi:10.1111/liv.13308.
    • (2017) Liver Int , vol.37 , pp. 173-178
    • Björnsson, E.S.1
  • 8
    • 84952066804 scopus 로고    scopus 로고
    • Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia
    • Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci 61: 1714–1720, 2016. doi:10.1007/s10620-015-4000-6.
    • (2016) Dig Dis Sci , vol.61 , pp. 1714-1720
    • Blais, P.1    Lin, M.2    Kramer, J.R.3    El-Serag, H.B.4    Kanwal, F.5
  • 10
    • 2142768218 scopus 로고    scopus 로고
    • Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
    • Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126: 1287–1292, 2004. doi:10.1053/j.gastro.2004.02.015.
    • (2004) Gastroenterology , vol.126 , pp. 1287-1292
    • Chalasani, N.1    Aljadhey, H.2    Kesterson, J.3    Murray, M.D.4    Hall, S.D.5
  • 11
    • 84924910736 scopus 로고    scopus 로고
    • Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells
    • Chong LW, Hsu YC, Lee TF, Lin Y, Chiu YT, Yang KC, Wu JC, Huang YT. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol 15: 22, 2015. doi:10.1186/s12876-015-0248-8.
    • (2015) BMC Gastroenterol , vol.15 , pp. 22
    • Chong, L.W.1    Hsu, Y.C.2    Lee, T.F.3    Lin, Y.4    Chiu, Y.T.5    Yang, K.C.6    Wu, J.C.7    Huang, Y.T.8
  • 14
    • 34249342305 scopus 로고    scopus 로고
    • Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study
    • Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47: 135–141, 2007. doi:10.1016/j.jhep.2007.02.013.
    • (2007) J Hepatol , vol.47 , pp. 135-141
    • Ekstedt, M.1    Franzén, L.E.2    Mathiesen, U.L.3    Holmqvist, M.4    Bodemar, G.5    Kechagias, S.6
  • 16
    • 84925851378 scopus 로고    scopus 로고
    • A century of cholesterol and coronaries: From plaques to genes to statins
    • Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161: 161–172, 2015. doi:10.1016/j.cell.2015.01.036.
    • (2015) Cell , vol.161 , pp. 161-172
    • Goldstein, J.L.1    Brown, M.S.2
  • 18
    • 84991824182 scopus 로고    scopus 로고
    • Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction
    • Gruzdeva O, Uchasova E, Dyleva Y, Akbasheva O, Karetnikova V, Barbarash O. Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction. Front Pharmacol 7: 324, 2016. doi:10.3389/fphar.2016.00324.
    • (2016) Front Pharmacol , vol.7 , pp. 324
    • Gruzdeva, O.1    Uchasova, E.2    Dyleva, Y.3    Akbasheva, O.4    Karetnikova, V.5    Barbarash, O.6
  • 20
    • 14044265120 scopus 로고    scopus 로고
    • Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids
    • Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 102: 2561–2566, 2005. doi:10.1073/pnas.0409834102.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 2561-2566
    • Kapadia, S.B.1    Chisari, F.V.2
  • 22
    • 85082452344 scopus 로고    scopus 로고
    • Statin (3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents
    • Kishta SS, Kishta SA, El-Shenawy R. Statin (3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. F1000 Res 5: 223, 2016. doi:10.12688/f1000research.7970.2.
    • (2016) F1000 Res , vol.5 , pp. 223
    • Kishta, S.S.1    Kishta, S.A.2    El-Shenawy, R.3
  • 24
    • 0034533147 scopus 로고    scopus 로고
    • Statins as a newly recognized type of immunomodulator
    • Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399–1402, 2000. doi:10.1038/82219.
    • (2000) Nat Med , vol.6 , pp. 1399-1402
    • Kwak, B.1    Mulhaupt, F.2    Myit, S.3    Mach, F.4
  • 25
    • 36348987648 scopus 로고    scopus 로고
    • Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial
    • Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46: 1453–1463, 2007. doi:10.1002/hep.21848.
    • (2007) Hepatology , vol.46 , pp. 1453-1463
    • Lewis, J.H.1    Mortensen, M.E.2    Zweig, S.3    Fusco, M.J.4    Medoff, J.R.5    Belder, R.6
  • 26
    • 84941281919 scopus 로고    scopus 로고
    • KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins
    • Marrone G, Maeso-Díaz R, García-Cardena G, Abraldes JG, García- Pagán JC, Bosch J, Gracia-Sancho J. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 64: 1434–1443, 2015. doi:10.1136/gutjnl-2014-308338.
    • (2015) Gut , vol.64 , pp. 1434-1443
    • Marrone, G.1    Maeso-Díaz, R.2    García-Cardena, G.3    Abraldes, J.G.4    García- Pagán, J.C.5    Bosch, J.6    Gracia-Sancho, J.7
  • 27
    • 84871211218 scopus 로고    scopus 로고
    • The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins
    • Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García- Pagán JC, Bosch J, Gracia-Sancho J. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol 58: 98–103, 2013. doi:10.1016/j.jhep.2012.08.026.
    • (2013) J Hepatol , vol.58 , pp. 98-103
    • Marrone, G.1    Russo, L.2    Rosado, E.3    Hide, D.4    García-Cardeña, G.5    García- Pagán, J.C.6    Bosch, J.7    Gracia-Sancho, J.8
  • 29
    • 84888339170 scopus 로고    scopus 로고
    • Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology
    • Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere J-P, Schwabe RF. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 4: 2823, 2013. doi:10.1038/ncomms3823.
    • (2013) Nat Commun , vol.4 , pp. 2823
    • Mederacke, I.1    Hsu, C.C.2    Troeger, J.S.3    Huebener, P.4    Mu, X.5    Dapito, D.H.6    Pradere, J.-P.7    Schwabe, R.F.8
  • 31
    • 84959470927 scopus 로고    scopus 로고
    • Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis
    • Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150: 430–40, 2016. doi:10.1053/j.gastro.2015.10.007.
    • (2016) Gastroenterology , vol.150 , pp. 430-440
    • Mohanty, A.1    Tate, J.P.2    Garcia-Tsao, G.3
  • 33
    • 74949102941 scopus 로고    scopus 로고
    • A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial
    • Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 43: 990–994, 2009. doi:10.1097/MCG.0b013e31819c392e.
    • (2009) J Clin Gastroenterol , vol.43 , pp. 990-994
    • Nelson, A.1    Torres, D.M.2    Morgan, A.E.3    Fincke, C.4    Harrison, S.A.5
  • 35
    • 84982839220 scopus 로고    scopus 로고
    • Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals
    • August 3
    • Oliver NT, Hartman CM, Kramer JR, Chiao EY. Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. AIDS (August 3, 2016). doi:10.1097/QAD.0000000000001219.
    • (2016) AIDS
    • Oliver, N.T.1    Hartman, C.M.2    Kramer, J.R.3    Chiao, E.Y.4
  • 36
    • 84865628946 scopus 로고    scopus 로고
    • Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis
    • Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157: 263–275, 2012. doi:10.7326/0003-4819-157-4-201208210-00007.
    • (2012) Ann Intern Med , vol.157 , pp. 263-275
    • Palmer, S.C.1    Craig, J.C.2    Navaneethan, S.D.3    Tonelli, M.4    Pellegrini, F.5    Strippoli, G.F.6
  • 37
    • 84919632658 scopus 로고    scopus 로고
    • The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease
    • Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 47: 4–7, 2015. doi:10.1016/j.dld.2014.07.170.
    • (2015) Dig Liver Dis , vol.47 , pp. 4-7
    • Pastori, D.1    Polimeni, L.2    Baratta, F.3    Pani, A.4    Del Ben, M.5    Angelico, F.6
  • 40
    • 79952010116 scopus 로고    scopus 로고
    • Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK
    • Relja B, Meder F, Wang M, Blaheta R, Henrich D, Marzi I, Lehnert M. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol 38: 879–885, 2011. doi:10.3892/ijo.2010.892.
    • (2011) Int J Oncol , vol.38 , pp. 879-885
    • Relja, B.1    Meder, F.2    Wang, M.3    Blaheta, R.4    Henrich, D.5    Marzi, I.6    Lehnert, M.7
  • 41
    • 85009471306 scopus 로고    scopus 로고
    • A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats
    • Rodríguez S, Raurell I, Torres-Arauz M, García-Lezana T, Genescà J, Martell M. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci Rep 7: 40461, 2017. doi:10.1038/srep40461.
    • (2017) Sci Rep , vol.7 , pp. 40461
    • Rodríguez, S.1    Raurell, I.2    Torres-Arauz, M.3    García-Lezana, T.4    Genescà, J.5    Martell, M.6
  • 43
    • 70449096299 scopus 로고    scopus 로고
    • Drug-induced liver injury associated with statins
    • Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 29: 412–422, 2009. doi:10.1055/s-0029-1240010.
    • (2009) Semin Liver Dis , vol.29 , pp. 412-422
    • Russo, M.W.1    Scobey, M.2    Bonkovsky, H.L.3
  • 45
    • 84976491135 scopus 로고    scopus 로고
    • Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
    • Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 64: 47–57, 2016. doi:10.1002/hep.28506.
    • (2016) Hepatology , vol.64 , pp. 47-57
    • Simon, T.G.1    Bonilla, H.2    Yan, P.3    Chung, R.T.4    Butt, A.A.5
  • 46
    • 84881491358 scopus 로고    scopus 로고
    • Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis
    • Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144: 323–332, 2013. doi:10.1053/j.gastro.2012.10.005.
    • (2013) Gastroenterology , vol.144 , pp. 323-332
    • Singh, S.1    Singh, P.P.2    Singh, A.G.3    Murad, M.H.4    Sanchez, W.5
  • 49
    • 34547469050 scopus 로고    scopus 로고
    • Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase
    • Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242–253, 2007. doi:10.1002/hep.21673.
    • (2007) Hepatology , vol.46 , pp. 242-253
    • Trebicka, J.1    Hennenberg, M.2    Laleman, W.3    Shelest, N.4    Biecker, E.5    Schepke, M.6    Nevens, F.7    Sauerbruch, T.8    Heller, J.9
  • 51
    • 84921385810 scopus 로고    scopus 로고
    • Etiology and Complications of Portal Vein Thrombosis
    • Trebicka J, Strassburg CP. Etiology and Complications of Portal Vein Thrombosis. Viszeralmedizin 30: 375–380, 2014. doi:10.1159/000369987.
    • (2014) Viszeralmedizin , vol.30 , pp. 375-380
    • Trebicka, J.1    Strassburg, C.P.2
  • 52
  • 54
    • 84945437158 scopus 로고    scopus 로고
    • Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection
    • Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, Chen PC. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 63: 1111–1117, 2015. doi:10.1016/j.jhep.2015.07.006.
    • (2015) J Hepatol , vol.63 , pp. 1111-1117
    • Yang, Y.H.1    Chen, W.C.2    Tsan, Y.T.3    Chen, M.J.4    Shih, W.T.5    Tsai, Y.H.6    Chen, P.C.7
  • 55
    • 33747810129 scopus 로고    scopus 로고
    • Intrahepatic upregulation of RhoA and Rhokinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis
    • Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, Sauerbruch T, Heller J. Intrahepatic upregulation of RhoA and Rhokinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55: 1296–1305, 2006. doi:10.1136/gut.2005.081059.
    • (2006) Gut , vol.55 , pp. 1296-1305
    • Zhou, Q.1    Hennenberg, M.2    Trebicka, J.3    Jochem, K.4    Leifeld, L.5    Biecker, E.6    Sauerbruch, T.7    Heller, J.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.